Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
br Conclusions br Conflicts of interest
2021-11-02
Conclusions Conflicts of interest Funding The research work was partially supported by National Science Center (Contract Grant Number: UMO-2015/19/B/NZ1/00332). Introduction Frusectose-1, 6-bisphosphatase (FBPase) has long been recognized as a potential therapeutic target for the treatm
-
Cell stiffness is determined by the cytoskeleton an intracel
2021-11-02
Cell stiffness is determined by the cytoskeleton, an intracellular polymeric network consisting of PRIMA-1MET receptor filaments, microtubules, intermediate filaments, and crosslinking proteins [38]. Low cell stiffness has been correlated with reduced formation of well-defined F-actin filaments or
-
We have expanded these studies by doing
2021-11-02
We have expanded these studies by doing EEG recording in the ET-1 model. Using this technique, we demonstrated that activation of either the ETA Gastrodin synthesis or the ETB receptor induces electrical seizures. ET-1 induced electrical seizures occurred in the presence of either the ETA receptor
-
PD153035 hydrochloride In this study according to the critic
2021-11-02
In this study, according to the critical pharmacophore T31, Y113 and R140 of FBPase, using the strategy of pharmacophore-based virtual screening, a series of novel scaffold inhibitor targeted the AMP binding site of FBPase were screened, their inhibitory activities against FBPase were further tested
-
br An approach for the key
2021-11-01
An approach for the key challenges facing forensic science One of the key challenges for forensic science is to avoid being side-tracked by one of the louder narratives in the media that the big problem forensic science faces is ‘junk science’ and ‘rogue scientists’. These are clearly important i
-
The involvement of prostaglandins on the effects induced by
2021-11-01
The involvement of prostaglandins on the effects induced by 1-nitro-2-phenylethane is similarly unlikely because vasorelaxation was not changed by indomethacin [20]. The inhibition of adenylyl cyclase with MDL-12330A [21] or cAMP-dependent protein kinase A with KT-5720 [22] also did not interfere w
-
br Acknowledgments br Introduction Obesity and type diabetes
2021-11-01
Acknowledgments Introduction Obesity and type 2 diabetes (T2D) are two major chronic non-communicable diseases that are increasing worldwide at an alarming rate; the majority of people with T2D are overweight or obese, and T2D associated with obesity is expected to have doubled by 2030 (Chen e
-
Post translational ubiquitination has been shown to regulate
2021-11-01
Post-translational ubiquitination has been shown to regulate a wide range of cellular responses, such as the synaptic trafficking and turnover of neurotransmitter receptors (Rape, 2018). Ubiquitination is also engaged in the modification of protein-protein interaction and intracellular signaling tra
-
The structure and activity of GLUT
2021-11-01
The structure and activity of GLUT1 has been most intensively studied in erythrocytes, in which this transporter makes up 10–20% of membrane protein content. Carruthers has shown that, while GLUT1 can exist and transport glucose as monomers, dimers and tetramers, in erythrocytes GLUT1 exists predomi
-
How do myofibroblast sources compare between bone marrow
2021-11-01
How do myofibroblast sources compare between bone marrow and other organs? Perivascular RS-1 with MSC properties significantly contribute to fibrosis in muscle, fat, skin, heart, kidney, lung, and liver (reviewed in Iwayama et al., 2015) and activate Gli1 in many of these organs (Kramann et al., 20
-
Herein exploiting several spectroscopic techniques i
2021-11-01
Herein, exploiting several spectroscopic techniques, i.e. CD, UV and NMR, along with gel electrophoresis, size exclusion chromatography and in silico prediction analysis, the conformational behaviour of R1.2 and R1.3 was studied in Na+- and K+-rich solutions, which mimic the extra- and intracellular
-
The intestinal epithelium is the first
2021-11-01
The intestinal epithelium is the first line of defense against pathogens and noxious agents and exerts a range of physiological activities, including digestion and orexin antagonist of nutrients. The intestinal wall consists of a series of finger shaped protrusions called villi and invaginations kn
-
Sirolimus rapamycin and everolimus both of which
2021-11-01
Sirolimus (rapamycin) and everolimus, both of which are mTOR inhibitors, are released by commonly used first- and second-generation DES. Considering the relatively high rates of the target vessel failure with currently available DES [12,14,16,45,46], there is a need for a novel drug strategy that pr
-
summarizes FAAH inhibition data for a series of benzofuran y
2021-11-01
summarizes FAAH inhibition data for a series of 4-[2-benzofuran]2-yl-pyrimidines substituted with a pyrrolidine, piperidine or homopiperidine bearing a methyl-ketobenzimidazole unit. As indicated, the 3-(keto-benzimidazole-3-yl)piperidine displayed potent inhibition of hFAAH and moderate inhibitio
-
Two recently developed highly specific EZH enzymatic
2021-11-01
Two recently developed, highly specific EZH2 enzymatic inhibitors, GSK126 and EPZ-6438, are currently in clinical trials for treating lymphomas (Kim and Roberts, 2016). Although these EZH2 inhibitors have shown antitumor effects in lymphoma cells with enzyme-activating mutations of EZH2 (Knutson et
15741 records 531/1050 page Previous Next First page 上5页 531532533534535 下5页 Last page